Three kinds of drug-eluting bead transarterial chemoembolisation for treating patients with unresectable non-small cell lung cancer

Table 1 Clinical characteristics of enrolled patients who underwent drug-eluting bead transarterial chemoembolization, n (%)/mean ± SD/median (25^th-75^th percentiles)

	DOX group	OXA group	GEM group	P value
Total number of patients	47	29	47
Gender (male)	38 (80.9)	19 (65.5)	38 (80.9)	0.23
Gender (female)	9 (19.1)	10 (34.5)	9 (19.1)	0.23
Mean age, years	60.5 ± 9.6	62.9 ± 13.4	65.9 ± 10.3	0.06
Course of disease (months)	3.5 (1.0-12.0)	3.0 (1.0-6.8)	3.0 (0.5-8.0)	0.57
Chemotherapy	15 (31.9)	10 (34.5)	20 (42.6)	0.54
Radiotherapy or chemoradiotherapy	6 (12.8)	3 (10.3)	2 (4.3)	0.34
Genetic mutations	4 (8.5)	6 (20.7)	8 (17.0)	0.29
Targeted therapy	7 (14.9)	8 (27.6)	6 (12.8)	0.22
Immunotherapy	5 (10.6)	2 (6.9)	11 (23.4)	0.09
Targeted and Immunotherapy	2 (4.3)	4 (13.8)	4 (8.5)	0.33
Tyrosine kinase inhibitors	8 (17.0)	10 (34.5)	8 (17.0)	0.24
Bevacizumab	1 (2.1)	2 (6.9)	2 (4.3)	0.59
Only one tumor	34 (72.3)	20 (69.0)	34 (72.3)
Two tumors	2 (4.3)	0 (0.0)	6 (12.8)	0.12
Not less than three tumors	11 (23.4)	9 (31.0)	7 (14.9)
Diameter of tumor (mm)	67.0 (48.0-88.9)	49.9 (37.4-74.5)	66.0 (49.0-84.0)	0.20
Lymph node metastasis	14 (29.8)	8 (27.6)	18 (38.3)	0.55
Distant organ metastasis	10 (21.3)	10 (34.5)	12 (25.5)	0.47
Squamous carcinoma	24 (51.1)	11 (37.9)	33 (70.2)
Adenocarcinoma	14 (29.8)	12 (41.4)	11 (23.4)	0.06
Other pathological types	9 (19.1)	6 (20.7)	3 (6.4)
II stage	1 (2.2)	4 (13.8)	4 (8.5)
III stage	19 (40.4)	9 (31.0)	19 (40.4)	0.38
IV stage	27 (57.4)	16 (55.2)	24 (51.1)	-
Central type	25 (53.2)	19 (65.5)	29 (61.7)	0.38
Peripheral type	22 (46.8)	10 (34.5)	18 (38.3)	0.38
Location, right lung	30 (63.8)	18 (62.1)	29 (61.7)	0.98
Location, left lung	14 (29.8)	11 (37.9)	16 (34.0)	0.76
Hemoptysis	18 (38.3)	7 (24.1)	13 (27.7)	0.36
Obstructive atelectasis or pneumonia	12 (25.5)	13 (44.8)	17 (36.2)	0.21

DOX: Doxorubicin; OXA: Oxaliplatin; GEM: Gemcitabine.